Saroglitazar
|
|
|
- CAS-Nr.
- 495399-09-2
- Englisch Name:
- Saroglitazar
- Synonyma:
- Saroglitazar;Saroglitazar, 10 mM in DMSO;(S)-2-Ethoxy-3-(4-(2-(2-methyl-5-(4-(methylthio)phenyl)-1H-pyrrol-1-yl)ethoxy)phenyl)propanoic acid;Benzenepropanoic acid, α-ethoxy-4-[2-[2-methyl-5-[4-(methylthio)phenyl]-1H-pyrrol-1-yl]ethoxy]-, (αS)-
- CBNumber:
- CB62708940
- Summenformel:
- C25H29NO4S
- Molgewicht:
- 439.57
- MOL-Datei:
- 495399-09-2.mol
|
Saroglitazar Eigenschaften
- Siedepunkt:
- 621.0±55.0 °C(Predicted)
- Dichte
- 1.15±0.1 g/cm3(Predicted)
- storage temp.
- Refrigerator
- L?slichkeit
- Chloroform (Slightly), DMSO (Slightly), Methanol (Slightly)
- pka
- 3.60±0.10(Predicted)
- Aggregatzustand
- Gel
- Farbe
- Red
- InChI
- InChI=1/C25H29NO4S/c1-4-29-24(25(27)28)17-19-6-10-21(11-7-19)30-16-15-26-18(2)5-14-23(26)20-8-12-22(31-3)13-9-20/h5-14,24H,4,15-17H2,1-3H3,(H,27,28)/t24-/s3
- InChIKey
- MRWFZSLZNUJVQW-FKEMPHOKNA-N
- SMILES
- C(N1C(=CC=C1C1C=CC(SC)=CC=1)C)COC1C=CC(C[C@@H](C(=O)O)OCC)=CC=1 |&1:22,r|
Sicherheit
- Risiko- und Sicherheitserkl?rung
- Gefahreninformationscode (GHS)
| Bildanzeige (GHS) |
|
| Alarmwort |
Warnung
|
| Gefahrenhinweise |
| Code |
Gefahrenhinweise |
Gefahrenklasse |
Abteilung |
Alarmwort |
Symbol |
P-Code |
| H302 |
Gesundheitssch?dlich bei Verschlucken. |
Akute Toxizit?t oral |
Kategorie 4 |
Warnung |
|
P264, P270, P301+P312, P330, P501 |
| H317 |
Kann allergische Hautreaktionen verursachen. |
Sensibilisierung der Haut |
Kategorie 1A |
Warnung |
|
P261, P272, P280, P302+P352,P333+P313, P321, P363, P501 |
|
| Sicherheit |
| P280 |
Schutzhandschuhe/Schutzkleidung/Augenschutz tragen. |
|
Saroglitazar Chemische Eigenschaften,Einsatz,Produktion Methoden
Beschreibung
Saroglitazar (also known as ZYH1) was approved for use by the Drug Controller General of India for the treatment of diabetic dyslipidemia and hypertriglyceridemia that is not controlled by statin therapy. Saroglitazar is the first approved agent with dual PPAR agonist activity, with EC
50s of 0.00065 and 3 nM, respectively, for the α- and γ-PPAR isoforms in HepG2 cells. The medicinal chemistry program has not been described in the scientific literature, but numerous substituents on the pyrrole ring are described in the saroglitazar patent. These substituted pyrroles were synthesized via ethanolamine condensation with substituted diketones and subsequent activation of the hydroxyethylpyrrole for phenolic etherification with (S)-2- ethoxy-3-(4-hydroxyphenyl)propanoic acid. The efficacy of saroglitazar was evaluated in db/db mice (genetically diabetic animals that lack the leptin receptor), wherein it produced a 17–55% reduction in serum triglycerides (TGs) after 12 days of administration of saroglitazar (0.01–3 mg/kg).
Verwenden
Saroglitazar, is a drug for the treatment of diabetic dyslipidemia and hypertriglyceridemia with Type 2 diabetes mellitus not controlled by statin therapy. Its trade name is Lipaglyn. It is also a 1,2-Diarylpyrroles derivative, which can be used in the preparation of Nonsteroidal anti-inflammatory drugs (NSAIDs).
Saroglitazar Upstream-Materialien And Downstream Produkte
Upstream-Materialien
Downstream Produkte
Saroglitazar Anbieter Lieferant Produzent Hersteller Vertrieb H?ndler.
Global( 74)Lieferanten
- Saroglitazar
- Benzenepropanoic acid, α-ethoxy-4-[2-[2-methyl-5-[4-(methylthio)phenyl]-1H-pyrrol-1-yl]ethoxy]-, (αS)-
- (S)-2-Ethoxy-3-(4-(2-(2-methyl-5-(4-(methylthio)phenyl)-1H-pyrrol-1-yl)ethoxy)phenyl)propanoic acid
- Saroglitazar, 10 mM in DMSO
- 495399-09-2
